MetaCap

Aardvark Therapeutics (AARD) vs Immutep (IMMP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immutep (IMMP) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 80.8% versus a loss of 90.2%. Immutep is the larger company by market cap ($22.9 million vs $20.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%IMMP+80.81%
+376%+132%-112%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%IMMP+58.67%
+318%+102%-113%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus IMMP key metrics
MetricAARDIMMP
Share price$0.9226$3.11
Market cap$20.20M$22.92M
1-day change-7.74%-9.06%
YTD return-92.97%+8.74%
1-year return-90.15%+80.81%
5-year return—-8.53%
EPS (TTM)$-3.33$-7.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-57.59M—
52-week high$16.60$70.60
52-week low$0.90$2.66
Distance from 52-week high-94.44%-95.59%
Analyst consensusbuynone
Avg. price target upside+1104.21%+864.63%
Average volume643.53K26.07K
Shares outstanding21.89M7.37M
Employees28—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMP has outperformed AARD by 171.0 percentage points over the past year.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Immutep

IMMP stock →

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations

AARD vs IMMP FAQ

Which is bigger, Aardvark Therapeutics or Immutep?

Immutep (IMMP) is larger, with a market capitalization of $22.92M compared with $20.20M for Aardvark Therapeutics (AARD).

Which stock has performed better over the past year, AARD or IMMP?

IMMP returned +80.81% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and Immutep in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons